Developing Therapies for Heart Failure With Preserved Ejection Fraction Current State and Future Directions

• Type of Material: Article
• Authors: Javed Butler, Emory University; Gregg C. Fonarow, University of California, Los Angeles; Michael R. Zile, Medical University of South Carolina; Carolyn S. Lam, National University Health System; Lothar Roessig, Bayer HealthCare; Erik B. Schelbert, University of Pittsburgh; Sanjiv J. Shah, Northwestern University; Ali Ahmed, University of Alabama Birmingham; Robert O. Bonow, Northwestern University; John GF Cleland, Castle Hill Hospital; Robert J. Cody, Janssen Pharmaceuticals; Ovidiu Chioncel, Institute of Emergency for Cardiovascular Diseases; Sean P. Collins, Vanderbilt University; Preston Dunnmon, US Food and Drug Administration; Gerasimos Filippatos, Attikon University Hospital; Martin P. Lefkowitz, Novartis Pharmaceuticals Inc.; Catherine N. Marti, Emory University; John J. McMurray, University of Glasgow; Frank Misselwitz, Bayer HealthCare; Vasiliki Georgiopoulou, Emory University
• Language: English
• Date: 2014-04-01
• Publisher: Elsevier: 12 months
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2014 American College of Cardiology Foundation.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.jchf.2013.10.006
• Title of Journal or Parent Work: JACC: Heart Failure
• ISSN: 2213-1779
• Volume: 2
• Issue: 2
• Start Page: 97
• End Page: 112
• Keywords: QUALITY-OF-LIFE; SYSTOLIC FUNCTION; preserved ejection fraction; treatment; Cardiovascular System & Cardiology; epidemiology; Science & Technology; RANDOMIZED CONTROLLED-TRIAL; VENTRICULAR DIASTOLIC DYSFUNCTION; heart failure; SINGLE-BLIND TRIAL; Cardiac & Cardiovascular Systems; EXERCISE CAPACITY; ELDERLY-PATIENTS; PRIOR MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE LEVELS; Life Sciences & Biomedicine; CONVERTING ENZYME-INHIBITORS; prognosis
• Research Categories: Health Sciences, Pharmacology; Health Sciences, Medicine and Surgery

Abstract

The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.